CDDO-Me alleviates oxidative stress in human mesenchymal stem cells

Mesenchymal stem cells (MSCs) have been recognized as a therapeutic tool for various diseases due to its unique ability for tissue regeneration and immune regulation. However, poor survival during in vitro expansion and after being administrated in vivo limits its clinical uses. Accordingly, protocols for enhancing cell survivability is critical for establishing an efficient cell therapy is needed. CDDO-Me is a synthetic C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, which is known to stimulate nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway. Herein, report that CDDO-Me promoted the proliferation of MSCs and increased colony forming units (CFU) numbers. No alteration in differentiation into tri-lineage mesodermal cells was found after CDDO-Me treatment. We observed that CDDO-Me treatment reduced the cell death induced by oxidative stress, demonstrated by the augment in the expression of Nrf2-downstream genes. Lastly, CDDO-Me led to the nuclear translocation of NRF2. Our data indicate that CDDO-Me can enhance the functionality of MSCs by stimulating cell survival and increasing viability under oxidative stress.

[1]  G. Rho,et al.  Porcine somatic cell nuclear transfer using telomerase reverse transcriptase-transfected mesenchymal stem cells reduces apoptosis induced by replicative senescence , 2020, Journal of Animal Reproduction and Biotechnology.

[2]  Yongmin Yan,et al.  Improved therapeutics of modified mesenchymal stem cells: an update , 2020, Journal of Translational Medicine.

[3]  A. Cossarizza,et al.  Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids , 2019, Molecules.

[4]  Ji-Eun Kim,et al.  CDDO-Me Selectively Attenuates CA1 Neuronal Death Induced by Status Epilepticus via Facilitating Mitochondrial Fission Independent of LONP1 , 2019, Cells.

[5]  Tae Min Kim,et al.  The Potential of Renal Progenitor Cells in Kidney Diseases: Preclinical Findings , 2019, Journal of Animal Reproduction and Biotechnology.

[6]  D. Covas,et al.  Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies , 2019, Stem Cell Research & Therapy.

[7]  G. Rho,et al.  Alteration of Apoptosis during Differentiation in Human Dental Pulp-Derived Mesenchymal Stem Cell , 2019, Journal of Animal Reproduciton and Biotechnology.

[8]  Jiang F Zhong,et al.  Mesenchymal Stem Cells: Characteristics, Function, and Application , 2019, Stem cells international.

[9]  D. Bueno,et al.  The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review , 2018, Front. Immunol..

[10]  C. Simmons,et al.  Mesenchymal Stromal/Stem Cells in Regenerative Medicine and Tissue Engineering , 2018, Stem cells international.

[11]  Hyeon-Jeong Lee,et al.  Trans-differentiation Induction of Human-mesenchymal Stem Cells Derived from Different Tissue Origin and Evaluation of their Potential for Differentiation into Corneal Epithelial-like Cells , 2018, Journal of Animal Reproduction and Biotechnology.

[12]  Ronnie H. Fang,et al.  Tissue repair and regeneration with endogenous stem cells , 2018, Nature Reviews Materials.

[13]  T. Ritter,et al.  Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning? , 2017, Front. Immunol..

[14]  A. Zajícová,et al.  Distinct Immunoregulatory Mechanisms in Mesenchymal Stem Cells: Role of the Cytokine Environment , 2016, Stem Cell Reviews and Reports.

[15]  A. Józkowicz,et al.  Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism , 2016, Cellular and Molecular Life Sciences.

[16]  Shufeng Zhou,et al.  Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties , 2014, Drug design, development and therapy.

[17]  N. Vaziri,et al.  Targeting the Transcription Factor Nrf2 to Ameliorate Oxidative Stress and Inflammation in Chronic Kidney Disease , 2012, Kidney international.

[18]  M. Konopleva,et al.  A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas , 2012, Clinical Cancer Research.

[19]  D. Ferguson,et al.  Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1. , 2011, American journal of physiology. Renal physiology.

[20]  R. Garrick.  Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes , 2011 .

[21]  M. Sporn,et al.  The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. , 2007, Cancer research.

[22]  M. Sporn,et al.  Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes , 2006, Molecular Cancer Therapeutics.

[23]  D. Kufe,et al.  Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. , 2006, The Journal of biological chemistry.

[24]  Paul Talalay,et al.  Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[26]  M. Sporn,et al.  Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. , 2000, Journal of medicinal chemistry.

[27]  A. Choi,et al.  Nrf2, a Cap’n’Collar Transcription Factor, Regulates Induction of the Heme Oxygenase-1 Gene* , 1999, The Journal of Biological Chemistry.